Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Rating of “Buy” from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have received a consensus recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.40.

Several brokerages have recently weighed in on RVPH. Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. D. Boral Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. Roth Mkm began coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $7.00 price target for the company. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Friday, January 10th. Finally, HC Wainwright dropped their price objective on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd.

Reviva Pharmaceuticals Price Performance

Reviva Pharmaceuticals stock opened at $1.09 on Thursday. The business has a fifty day moving average price of $1.56 and a 200-day moving average price of $1.48. The firm has a market capitalization of $36.45 million, a P/E ratio of -0.98 and a beta of -0.09. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $4.28.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in shares of Reviva Pharmaceuticals by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after purchasing an additional 42,376 shares in the last quarter. EMC Capital Management boosted its stake in Reviva Pharmaceuticals by 142.0% in the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after buying an additional 26,134 shares in the last quarter. Drive Wealth Management LLC bought a new position in Reviva Pharmaceuticals during the fourth quarter valued at approximately $36,000. Ameriprise Financial Inc. purchased a new position in shares of Reviva Pharmaceuticals during the fourth quarter worth approximately $84,000. Finally, Tang Capital Management LLC bought a new stake in shares of Reviva Pharmaceuticals in the 4th quarter worth approximately $308,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.